Phagocytosis of Apoptotic Cells in Resolution of Inflammation. by Kourtzelis, Ioannis et al.
This is a repository copy of Phagocytosis of Apoptotic Cells in Resolution of Inflammation..
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/159692/
Version: Published Version
Article:
Kourtzelis, Ioannis orcid.org/0000-0003-3006-8885, Hajishengallis, George and Chavakis, 
Triantafyllos (2020) Phagocytosis of Apoptotic Cells in Resolution of Inflammation. 
Frontiers in immunology. pp. 1-8. ISSN 1664-3224 
https://doi.org/10.3389/fimmu.2020.00553
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
MINI REVIEW
published: 31 March 2020
doi: 10.3389/fimmu.2020.00553
Edited by:
Esther M. Lafuente,
Complutense University of Madrid,
Spain
Reviewed by:
Amiram Ariel,
University of Haifa, Israel
Jeffrey Louis Curtis,
University of Michigan Medical
School, United States
*Correspondence:
Ioannis Kourtzelis
ioannis.kourtzelis@york.ac.uk
Specialty section:
This article was submitted to
Molecular Innate Immunity,
a section of the journal
Frontiers in Immunology
Received: 12 January 2020
Accepted: 11 March 2020
Published: 31 March 2020
Citation:
Kourtzelis I, Hajishengallis G and
Chavakis T (2020) Phagocytosis
of Apoptotic Cells in Resolution
of Inflammation.
Front. Immunol. 11:553.
doi: 10.3389/fimmu.2020.00553
Phagocytosis of Apoptotic Cells in
Resolution of Inflammation
Ioannis Kourtzelis1,2* , George Hajishengallis3 and Triantafyllos Chavakis1,4
1 Institute for Clinical Chemistry and Laboratory Medicine, University Hospital and Faculty of Medicine, Technische Universität
Dresden, Dresden, Germany, 2 Hull York Medical School, York Biomedical Research Institute, University of York, York,
United Kingdom, 3 Laboratory of Innate Immunity and Inflammation, Penn Dental Medicine, Department of Basic
and Translational Sciences, University of Pennsylvania, Philadelphia, PA, United States, 4 Centre for Cardiovascular Science,
Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom
Efficient inflammation resolution is important not only for the termination of the
inflammatory response but also for the restoration of tissue integrity. An integral process
to resolution of inflammation is the phagocytosis of dying cells by macrophages,
known as efferocytosis. This function is mediated by a complex and well-orchestrated
network of interactions amongst specialized phagocytic receptors, bridging molecules,
as well as “find-me” and “eat-me” signals. Efferocytosis serves not only as a waste
disposal mechanism (clearance of the apoptotic cells) but also promotes a pro-resolving
phenotype in efferocytic macrophages and thereby termination of inflammation.
Alterations in cellular metabolism are critical for shaping the phenotype and function of
efferocytic macrophages, thus, representing an important determinant of macrophage
plasticity. Impaired efferocytosis can result in inflammation-associated pathologies or
autoimmunity. The present mini review summarizes current knowledge regarding the
mechanisms regulating macrophage efferocytosis during clearance of inflammation.
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INTRODUCTION
Specific recognition and engulfment of “foreign” material or pathogens by host cells, designated
as phagocytosis, is an essential process modulating the immune response and tissue homeostasis
(1, 2). Besides phagocytosis of opsonized pathogens by phagocytes during an infection, host cells
undergoing apoptosis are also cleared by macrophages; the specific phagocytosis of dying cells by
macrophages is designated efferocytosis (3). The specific pathways for phagocytosis of different
types of cargo point to the versatility of the phagocytic machinery (1, 2).
A central player in sterile inflammation or inflammation associated with infection are
neutrophils recruited to the inflamed site (4, 5). Recruited neutrophils phagocytose and kill
pathogens, produce reactive oxygen species (ROS) and pro-inflammatory factors, such as
cytokines, and can either release neutrophil extracellular traps (NETs) or undergo apoptosis (4–
6). Efferocytosis is therefore of great importance in the regulation of neutrophilic inflammation (3,
7–10). Effective removal of dying neutrophils promotes not only inflammation resolution but also
contributes to restoration of tissue and organ homeostasis (3). A complex network of interactions
between receptors mediating phagocytosis, bridging molecules, “find-me” and “eat-me” signals,
such as phosphatidylserine (PS), which is presented on the outer part of the membrane of cells
undergoing apoptosis, contributes to the formation of phagocytic synapse (Figure 1) and the
operation of the efferocytic machinery (7, 8, 11). As resolution of inflammation occurs, efferocytic
macrophages acquire a resolving phenotype producing factors that dampen inflammation and
promote restoration of tissue integrity, such as IL-10 or transforming growth factor β (TGFβ) (3),
a
Frontiers in Immunology | www.frontiersin.org 1 March 2020 | Volume 11 | Article 553
Kourtzelis et al. Efferocytosis and Macrophage Metabolism
FIGURE 1 | The structure of engulfment synapse. During efferocytosis, the clearance of apoptotic cells by macrophages is orchestrated by the recognition of the
major “eat-me” signal PS, either directly by PS receptors or via bridging molecules that mediate binding of PS to phagocytic receptors. Depicted are a few examples
of phagocytic receptors and bridging molecules that are described in the text (see text for primary references).
as well as specialized pro-resolving lipid mediators (SPM), such
as resolvins, lipoxins, and maresins (9, 12). SPM synthesis can
further promote efferocytosis, thereby further potentiating
inflammation resolution (9, 12). Defective removal of apoptotic
cells resulting from impaired efferocytosis can lead to chronicity
of inflammation and development of inflammatory disorders,
such as atherosclerosis and autoimmune diseases (9, 13–15).
Emerging evidence suggests that macrophage function
is regulated by alterations in their cellular metabolism in
response to environmental cues within the inflammatory
milieu (16). For instance, specific metabolic components
may promote or suppress inflammatory responses in
macrophages (16). Importantly, efferocytosis also promotes
immunometabolic reprograming in macrophages (17)
(Figure 2). For example, digestion of the engulfed apoptotic
cargo through phagolysosomal activity results in a load of lipid
components derived from the apoptotic cell membranes that is
linked to enhanced fatty acid oxidation and regulatesmacrophage
function (17–19). The mechanisms underlying apoptotic cell
removal by macrophages as well as the immunometabolic
alterations in efferocytic macrophages during inflammation
resolution is the focus of the present review.
MOLECULAR CROSS-TALK BETWEEN
APOPTOTIC CELLS AND
MACROPHAGES DURING
EFFEROCYTOSIS
The engulfment of dying cells by efferocytic macrophages
requires the recognition of the former by the latter and the
formation of the engulfment synapse, which is regulated by
a network of “find-me,” “eat-me” and bridging molecules,
“don’t eat-me” signals and specialized phagocytic receptors
(11) (Figure 1). Neutrophils undergoing apoptosis during an
inflammatory response, secrete molecules serving as “find-
me” signals that can attract phagocytes to eliminate apoptotic
cell corpses (20, 21). These include the nucleotides adenosine
triphosphate (ATP) and uridine triphosphate (UTP), which are
recognized by the macrophage purinergic receptor P2Y2 (22), or
the lipids lysophosphatidylcholine (LPC) (23) and sphingosine-
1-phosphate (24), which bind to macrophage G-protein-
coupled receptors G2A and S1P1-5, respectively. Furthermore,
recognition of dying cells by macrophages may be facilitated
by the interaction of intercellular adhesion molecule 3 (ICAM3
or CD50) on the former with CD14 on macrophages (25) as
well as by the thrombospondin (TSP1)–CD36 interaction (26).
Moreover, the specific recognition of apoptotic cells is ensured by
the presence of “eat-me” signals. PS is the most well characterized
“eat-me” signal (Figure 1). During apoptosis, this phospholipid
is found on the outer part of the membrane and binds directly
or indirectly, via bridging molecules (opsonins), to phagocytic
receptors (27, 28). Calreticulin (Crt) is a membrane-associated
protein that functions as an “eat-me” signal’ on the surface of
dying cells and is recognized by the LDL-receptor-related protein
1 (LRP1 or CD91) on phagocytes (29). The long pentraxin PTX3
may also act as an “eat-me” signal to facilitate the capture of dying
neutrophils by macrophages (30).
As alluded to above, bridging molecules are often key
to efficient interactions between apoptotic neutrophils and
macrophages (11). Milk fat globule-EGF factor 8 protein (MFG-
E8 or lactadherin) promotes efferocytosis by binding to PS
on apoptotic cells and to macrophage phagocytic integrin
receptors αvβ3 and αvβ5 (31, 32). MFG-E8 shares homology
with developmental endothelial locus-1 (DEL-1). Besides the
established anti-inflammatory role of DEL-1 as inhibitor of β2
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FIGURE 2 | Metabolic cues implicated in macrophage efferocytosis. Upon efferocytosis, increased glucose uptake via upregulated SLC2A1 and enhanced glycolysis
are linked with enhanced lactate release via SLC16A (102). The metabolism of arginine and ornithine to putrescine is involved in promoting continual efferocytosis
(105). In addition, enhanced lipid metabolism upon efferocytosis is associated with fatty acid oxidation and Sirtuin 1 (Sirt1)-dependent upregulation of IL-10 (18).
Moreover, activation of lipid transcription factors (e.g., the LXR/RXR or PPAR/RXR heterodimers) promotes the upregulation of bridging molecules and phagocytic
receptors and the resolving macrophage phenotype (107).
integrin-dependent leukocyte recruitment and IL-17-mediated
inflammation (8, 33–38) and its role as a regulator of
bone marrow myelopoiesis (39, 40), secreted DEL-1 promotes
engulfment of apoptotic cells and inflammation resolution
(41). In particular, DEL-1 functions as a molecular bridge
that binds concomitantly to PS on the apoptotic neutrophil
surface via its C-terminal discoidin I-like domains and to
αvβ3 integrin [also known as vitronectin receptor (42)] on
macrophages via its N-terminal RGD motif within the second
EGF-like domain (41, 43). Importantly, the compartmentalized
localization of DEL-1 differentially regulates the inflammatory
response. Specifically, the endothelial cell-derived molecule
promotes anti-inflammatory activity by blocking β2 integrin-
dependent leukocyte recruitment, whereas DEL-1 derived from
macrophages promotes efferocytosis-dependent resolution of
inflammation (33, 41) (Figure 1). Other molecules that act as
a molecular bridge to facilitate interactions between apoptotic
cargo and phagocytes include annexin A1 or lipocortin-1 (44),
β2-glycoprotein-I (β2-GPI) (45), and galectin-3 (Gal-3) (46).
Moreover, the bridging molecules Growth arrest-specific factor
6 (Gas6) and protein S have been implicated in PS-mediated
apoptotic cell clearance (47, 48) via interacting with the receptor
tyrosine kinases Tyro-3, Axl and Mer (TAM) (49–52) (Figure 1).
Phagocytic receptors on macrophages involved in the
regulation of efferocytosis include also the PS receptors of the
T-cell membrane protein (Tim) family, such as TIM-1 and
TIM-4 (53, 54). The brain angiogenesis inhibitor 1 (BAI1)
(55) and stabilin-2 (56) also serve as PS receptors (Figure 1).
Additionally, CD14, the scavenger receptor CD36, and the
integrin CD11b/CD18 (αMβ2) (besides the integrins αvβ5 and
αvβ3 that were mentioned above) are implicated as efferocytosis
receptors (8, 11, 26, 42, 57, 58).
The presence of “don’t eat-me” signals further adds
to the complexity of the regulation of apoptotic cell
clearance. Specifically, surface expression of CD47 (also
named integrin-associated protein) prevents phagocytosis by
macrophages (59, 60). Binding of CD47 to the macrophage signal
regulatory protein alpha (SIRPα) modulates rearrangement of
actin cytoskeleton, thereby downregulating phagocytosis (59,
60). However, apoptotic cells have decreased levels of CD47
that allows their clearance by macrophages (59–61). Platelet and
endothelial cell adhesion molecule 1 (PECAM-1, CD31) also
exerts a “don’t eat-me” function. In this regard, homotypic CD31
interaction between non-apoptotic neutrophils and macrophages
may prevent phagocytic clearance (62). Furthermore, CD24 (63)
and the complement receptor CD46 (64) have been described
as repulsive signals that interfere with efferocytosis. Decreased
presence or alterations in the distribution of “don’t eat-me”
signals have been associated with enhanced efferocytic activity
(65, 66).
Efficient efferocytosis is critical for shaping the pro-resolving
phenotype in macrophages that includes production of
immunomodulators, which in turn further enhance resolution
of inflammation (67–71). For instance, production of TGFβ
by efferocytic macrophages is a major orchestrator of
inflammation resolution. Indeed, upregulation of TGFβ
owing to efferocytosis promotes downregulation of the pro-
inflammatory mediators TNF, IL-1β and IL-8. Consistently,
antibody-mediated inhibition of TGFβ restored expression of
inflammatory mediators. Along the same line, administration
of apoptotic cells in vivo models of inflammation triggers
resolution of inflammation in a manner dependent on TGFβ
upregulation (72, 73). Additionally, interleukin 13 derived
from regulatory T cells acts on macrophages and promotes
production of IL-10, which in turn enhances efferocytosis
via activation of Rac1 GTPase and thereby inflammation
resolution in atherosclerosis (74). Besides the upregulation
of immune-modulating factors, such as TGFβ or IL-10,
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the direct inhibition of pro-inflammatory cytokines further
contributes to inflammation resolution. As an exemplar,
formation of NETs that aggregate at the inflamed site leads to
protease–dependent degradation of inflammatory cytokines and
chemokines, thereby promoting resolution of acute neutrophilic
inflammation (75).
The phenotype of efferocytic macrophages is additionally
controlled by the enzyme 12/15 lipoxygenase (12/15-LO) that
oxidizes polyunsaturated fatty acids and generates bioactive
lipid metabolites leading to the biosynthesis of pro-resolving
lipid mediators (9, 76). Specifically, apoptotic cell engulfment
can be performed by resident or monocyte-derived resolution
phase macrophages expressing 12/15-LO (77–80). Apoptotic cell
engulfment further promotes the expression of this enzyme
(81). Moreover, 12/15-LO has been implicated to function in
preventing induction of autoimmunity (77).
Plasminogen and its cleavage product plasmin not only
regulate the initiation but also the resolution phase of
inflammation. Treatment of mice with plasminogen/plasmin
resulted in recruitment of pro-resolving macrophages and in
upregulation of TGFβ. Administration of plasminogen/plasmin
at the peak of inflammation was associated with increased
neutrophil apoptosis and efferocytosis; the pro-resolving effect of
plasminogen was mediated by annexin A1 (82). In accordance,
impaired efferocytosis accompanied by decreased levels of
annexin A1 was observed in mice deficient in plasminogen
or its receptor (83). Besides being involved in pro-resolving
actions of plasminogen, annexin A1 plays a broader role in
inflammation resolution (84, 85). Annexin A1 levels are increased
in the resolution phase of monosodium urate crystal–induced
arthritis, a model of gout. Pharmacologic or genetic inactivation
of annexin A1 resulted in insufficient resolution of gout-related
inflammation in mice (86). In addition, treatment of mice with
annexin A1 resulted in upregulation of IL-10 and downregulation
of proinflammatory mediators, while, consistently, inhibition
of annexin A1 abrogated inflammation resolution induced by
glucocorticoids (87, 88).
Moreover, IFN-β from macrophages was recently identified
as a factor promoting resolution of inflammation. IFN-β
levels were higher in the resolution phase of pneumonia and
peritoneal inflammation. Activation of IFN-β signaling via
STAT3 enhances apoptosis of neutrophils and their subsequent
efferocytic clearance, resulting in a pro-resolving reprograming
of macrophages (79).
METABOLIC MODULATION OF
MACROPHAGE FUNCTION IN THE
CONTEXT OF EFFEROCYTOSIS
The impact of cellular metabolism on macrophage function
and plasticity has gained much attention recently (16, 89–91).
Metabolic pathways, such as glycolysis, tricarboxylic acid (TCA)
cycle, pentose phosphate pathway and fatty acid oxidation,
regulate macrophage phenotype in the context of inflammatory
responses (91). For instance, increased glycolytic flux has been
linked to pro-inflammatory M1-like activation of macrophages,
whereas oxidative phosphorylation is associated with anti-
inflammatory macrophage polarization (92).
Moreover, macrophage tissue specificity may be associated
with differential metabolic activity. For example, resident
peritoneal macrophage survival depends on the transcription
factor GATA6 that is regulated by the vitamin A metabolite
retinoic acid (93, 94), while the nuclear receptor liver × receptor
(LXR) alpha that is activated by lipids regulates differentiation of
marginal zone splenic macrophages (95). It is now established
that tissue-specific resident macrophages have distinct
transcriptomic profiles and phenotypes depending on the
particular microenvironment (96, 97). Importantly, in this
regard, the manner by which efferocytosis is regulated in resident
macrophages may be dictated by the tissue microenvironment.
Indeed, parabiosis-based experiments have revealed substantial
heterogeneity in the utilization of bridging molecules, efferocytic
receptors and transcription factors by macrophages from
different tissues. For instance, the mannose receptor CD206
is upregulated in phagocytic macrophages in bone marrow
and intestine but not in the spleen (98). Moreover, the profile
of upregulated anti-inflammatory mediators by efferocytic
macrophages is tissue-specific (98).
Regulation of macrophage metabolic activity in the context
of efferocytosis (Figure 2) is of major importance for the
outcome of inflammation resolution and tissue repair (99).
Following engulfment, macrophages degrade the apoptotic
material through phagolysosomal activity (100, 101), resulting
in substantial metabolic load and influence on macrophage
metabolism (17).
Aerobic glycolysis was recently implicated in regulation of
efferocytosis and shaping an anti-inflammatory environment
by efferocytic macrophages (102). Specifically, transcriptomic
analysis of macrophages engaging in active phagocytosis of
apoptotic cells revealed an upregulation of several members
of the solute carrier (SLC) membrane transport protein
family, including the glucose transporter protein type 1
(GLUT1; encoded by the gene Slc2a1) and monocarboxylate
transporter 1 (encoded by Slc16a1) promoting lactate release.
Enhanced glycolysis in efferocytic macrophages promoted actin
polymerization and continued uptake of apoptotic cells. On the
other hand, lactate from efferocytic macrophages contributed
to establishment of an anti-inflammatory phenotype of the
surrounding tissue (102) (Figure 2). Consistently, knockdown
of Slc16a1 in the setting of efferocytosis resulted in reduced
mRNA expression of factors linked to the resolving macrophage
phenotype and resolution of inflammation, such as Tgfb1
and Il10 (102). Furthermore, specific deletion of GLUT1 in
myeloid cells was associated with defective phagocytic ability
of macrophages and with development of unstable lesions
in a model of atherosclerosis (103). Moreover, deficiency of
the glycolytic enzyme 6-phosphofructose-2-kinase and fructose-
2,6-bisphosphatase (PFKFB3) in macrophages led to reduced
efferocytosis capacity, thus further supporting a role for glycolysis
in apoptotic cell clearance (104).
Metabolites derived from engulfed apoptotic cells serve
to fine-tune the process of efferocytosis and resolution of
inflammation. Apoptotic cells are a source of the amino acids
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arginine and ornithine that are metabolized in macrophages
to putrescine. This metabolic process enables continual
rounds of efferocytosis (Figure 2). Putrescine enhances,
via the RNA-binding protein HuR, the mRNA stabilization
of the GTP-exchange factor Dbl. Dbl in turn activates the
GTPase Rac1, resulting in changes in the actin cytoskeleton
that facilitate further apoptotic cell engulfment. Exogenous
administration of putrescine increases inflammation resolution
in the context of atherosclerosis. Consistently, deficiency in
myeloid cells of either the enzyme arginase 1 (Arg1), which
converts arginine to ornithine, or the enzyme ornithine
decarboxylase (ODC), which mediates the decarboxylation
of ornithine to putrescine (Figure 2), is associated with
efferocytic dysfunction and defective atherosclerosis
resolution (105).
Several lines of evidence support also an important role of
mitochondrial metabolism on the modulation of efferocytosis
and efferocytosis-dependent resolution of inflammation.
Metabolomic analysis of macrophages that have engulfed
apoptotic material revealed metabolic reprograming of
efferocytic macrophages toward fatty acid oxidation. Specifically,
upregulation of pro-resolving IL-10 in efferocytic macrophages
was mediated by mitochondrial beta-oxidation and induction
of sirtuin1 signaling (18) (Figure 2). The interplay between
mitochondrial activity and effective efferocytosis was also
illustrated by analyzing the function ofmitochondrial uncoupling
protein 2 (Ucp2). Besides its function in uncoupling oxidative
phosphorylation from synthesis of ATP, Ucp2 can promote
efferocytosis by reducing the mitochondrial membrane potential
of macrophages. In the same vein, deficiency of Ucp2 resulted
in defective apoptotic cell removal and was associated with
development of atherosclerosis, whereas overexpression of Ucp2
enhanced efferocytosis (19). Additionally, dynamic alterations
in mitochondrial physiology may dictate the outcome of
efferocytosis. In particular, a major component of mitochondrial
homeostasis, mitochondrial fission, mediated by the function
of the GTPase dynamin-related protein 1 (Drp1), positively
regulates continuous apoptotic cell removal by macrophages.
Accordingly, the absence of Drp1 was associated with higher
atherosclerosis development in low-density lipoprotein receptor
1 (Ldlr1) deficient mice (106).
Lipids deriving from the apoptotic cargo are abundant post-
engulfment digestion products (17); lipid metabolism induces
activation of the nuclear receptors peroxisome proliferator-
activated receptor (PPAR) gamma and delta, LXR alpha and
beta and retinoid × receptor (RXR) alpha and beta (107)
in macrophages (Figure 2). Activation of these transcription
factors promotes upregulation of phagocytic receptors and
bridgingmolecules and the resolvingmacrophage phenotype. For
instance, TGFβ and IL-10, which both promote inflammation
resolution, are upregulated in efferocyticmacrophages in an LXR-
and PPAR delta–dependent manner (108, 109). Importantly,
deficiency of these nuclear receptors has been linked to
defective efferocytosis and development of chronic inflammation
or autoimmune manifestations (108, 109). Moreover, LXR
activation is involved in DEL-1–dependent efferocytosis and
macrophage reprograming to a proresolving phenotype (41).
LXR signaling also regulates expression of transglutaminase 2
(Tgm2) (110), which acts as a co-receptor to αvβ3-integrin and
promotes formation of engulfing portals (111).
Cholesterol metabolism has been also implicated in the
modulation of efferocytosis. Treatment of macrophages with
the cholesterol-lowering drug lovastatin, which inhibits the
rate-limiting enzyme of cholesterol synthesis 3-hydroxyl-3-
methylglutaryl coenzyme A (HMG-CoA) reductase, leads to
increased apoptotic cell clearance (112). Administration of
another HMG-CoA reductase inhibitor, simvastatin, enhances
the efferocytosis-dependent amelioration of inflammation
in the context of lung fibrosis (113). Along the same line,
the ATP-binding cassette transporter (ABCA1), a protein
that modulates cholesterol efflux, is upregulated during
efferocytosis in a manner dependent on LXR signaling (114).
Furthermore, decreased hydrolysis of cholesterol esters and
impaired oxysterol production, due to blockade of the enzyme
lysosomal acid lipase, negatively affect LXR pathway activation
and apoptotic cell removal, resulting in chronic inflammation
(115). These studies point to the intimate crosstalk between
cholesterol metabolism and nuclear receptor signaling involved
in efferocytosis.
CONCLUDING REMARKS
Macrophage efferocytosis is a major player in resolution of
inflammation. Efferocytosis not only paves the way toward
the timely termination of the inflammatory response, but
also promotes restoration of tissue homeostasis. In this
context, alterations in macrophage cellular metabolism
are important regulators of efferocytosis. At the same
time, metabolic reprograming in efferocytic macrophages
induced by digested apoptotic material substantially regulates
the function and plasticity of efferocytic macrophages.
Given the relevance of efferocytosis as a mechanism
against chronic inflammatory disease, a better mechanistic
understanding of the pathways that orchestrate the mutual
interaction between clearance of dying cells and metabolic
alterations in macrophages is required. This knowledge will
provide a scaffold for designing therapeutic approaches to
improve macrophage function in inflammation resolution
and harness macrophage efferocytosis for the treatment
of pathologies associated with chronic inflammation
or autoimmunity.
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